




RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022



Navidea Biopharmaceuticals Inc. Rank 49 of 50



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022



Navidea Biopharmaceuticals Inc. Rank 49 of 50

The relative strengths and weaknesses of Navidea Biopharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Navidea Biopharmaceuticals Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 98% points. The greatest weakness of Navidea Biopharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 519% points.

The company's Economic Capital Ratio, given in the ranking table, is -741%, being 512% points below the market average of -229%.

Input Variable	Value in 1000 USD
Assets Hidden Reserves	0
Assets, Current	5,383
Assets, Non-Current	355
General and Administrative Expense	7,450
Goodwill	786
Liabilities Hidden Reserves	0
Liabilities, Current	5,300
Liabilities, Non-Current	20
Other Assets	0
Other Compr. Net Income	0
Other Expenses	16
Other Liabilities	700
Other Net Income	346
Property, Plant and Equipment, Net	120
Research and Development	5,142
Revenues	532

Output Variable	Value in 1000 USD
Liabilities	6,020
Assets	6,645
Expenses	12,608
Market Value Liabilities	6,020
Market Value Assets	6,645
Stockholders Equity	625
Net Income	-11,731
Comprehensive Net Income	-11,731
Economic Capital Ratio	-741%



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai